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gmail.comSummaryAlternating between hyper- and hypo-thyroidism may be explained by the simultaneous presence of both types of TSH
receptor autoantibodies (TRAbs) – thyroid stimulating autoantibodies (TSAbs) and TSH blocking autoantibodies (TBAbs).
It is a very rare condition, particulary in the pediatric age. The clinical state of these patients is determined by the balance
between TSAbs and TBAbs and can change over time. Many mechanisms may be involved in fluctuating thyroid function:
hormonal supplementation, antithyroid drugs and levels of TSAbs and TBAbs. Frequent dose adjustments are needed in
order to achieve euthyroidism. A definitive therapy may be necessary to avoid switches in thyroid function and frequent need
of therapeutic changes. We describe an immune-mediated case of oscillating thyroid function in a 13-year-old adolescent.
After a short period of levothyroxine treatment, the patient switched to a hyperthyroid state that was only controlled by
adding an antithyroid drug.Learning points:
† Autoimmune alternating hypo- and hyper-thyroidism is a highly uncommon condition in the pediatric age.
† It may be due to the simultaneous presence of both TSAbs and TBAbs, whose activity may be estimated in vitro
through bioassays.
† The clinical state of these patients is determined by the balance between TSAbs and TBAbs and can change
over time.
† The management of this condition is challenging, and three therapeutic options could be considered: I-131 ablation,
thyroidectomy or pharmacological treatment (single or double therapy).
† Therapeutic decisions should be taken according to clinical manifestations and thyroid function tests, independent
of the bioassays results.
† A definitive treatment might be considered due to the frequent switches in thyroid function and the need for close
monitoring of pharmacological treatment. A definitive treatment might be considered due to the frequent switches
in thyroid function and the need for close monitoring of pharmacological treatment.Background
Autoimmune thyroid disease is one of the most common
autoimmune conditions, affecting 2–4% of women and
1% of men (1). Although its prevalence is higher in adults,
it is also the most frequent etiology of acquired thyroiddysfunction in pediatrics. In this population, it is most
common in girls and generally occurs in early and mid-
puberty (2).
Autoimmune thyroid disease encompasses an ample
spectrum of thyroid disorders from which Hashimoto’shttp://www.edmcasereports.com
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presentations. They represent the two ends of the auto-
immune thyroid disease spectrum once they have opposite
phenotypes and distinct immunologic mechanism. At first,
there is T-cell infiltration of the gland leading to its
destruction and clinical signs of hypothyroidism; finally,
the gland is chronically stimulated by agonist antibodies of
thyroid-stimulating hormone (TSH) receptor, produced by
local B cells, causing hyperthyroidism.
However, there is an interrelationship between the
various autoimmune thyroid disorders that could be
explained by a common pathophysiological mechanism
and antibody production. The thyroid gland releases
antibodies against specific antigens, more frequently
against thyroglobulin, thyroid peroxidase and TSH
receptor. Elevated levels of antithyroglobulin and antithy-
roid peroxidase antibodies may not only be found in
patients with autoimmune thyroid disease but also in
healthy individuals, with a prevalence of 5–30% in the
general population. The TSH-receptor antibodies (TRAbs)
are more specific for autoimmune thyroid disease. Their
prevalence in Graves’ disease and autoimmune thyroiditis
is 80–95% and 10–20%, respectively (3).
There are two types of TRAbs: thyroid-stimulating
autoantibodies (TSAbs) that cause Graves’ disease and TSH-
blocking autoantibodies (TBAbs), competitive inhibitors of
TSH binding sites without agonistic activity. TBAbs are
found in a significant number (18.5%) of adult patients with
untreated Graves’ disease; however, TBAbs-induced hypo-
thryoidism is a very rare condition (4, 5). Some patients may
have TBAbs and TSAbs sequentially and evolve from hypo-
to hyperthyroidism or vice versa. In very few adult patients,
both antibodies may be present simultaneously, leading to
a rapid oscillation in thyroid function as TBAbs or TSAbs
become dominant (5). This situation is even more
uncommon in pediatric population (4). The TRAbs activity
may be estimated in vitro through bioassays. The more
sophisticated ones involve chinese hamster ovary cells
(CHO cells) transfected with the recombinant human TSH-
receptor. The biological activity is deduced through cyclic
adenosine 30,50-monophosphate (cAMP) production (6, 7).
Herein, we report a case of an adolescent with
fluctuating thyroid function associated with elevated
levels of antithyroglobulin, antithyroid peroxidase and
TSH-receptor antibodies.Case presentation
A previously healthy 13-year-old girl, referred for evalu-
ation, presented in the clinic with a slightly increasedhttp://www.edmcasereports.comthyroid volume, and a subclinical hyperthyroidism
observed in June 2012, with no signs or symptoms
(table 1). There was family history of thyroid disease.
On first evaluation, in March 2013, she presented a
visible and palpable thyroid gland with no individualized
nodules, no adenomegaly, and no exophthalmos. There
were no other relevant findings in her physical exam. The
TSH and free-thyroxine (fT4) serum levels were within the
normal range, but she presented with elevated levels of
antithyroid peroxidase antibodies (Table 1). The thyroid
ultrasound confirmed a diffuse glandular enlargement
(right lobe 18!16!46 mm; left lobe 16!16!51 mm),
with an heterogeneous and hypoechoic parenchymal
echo pattern suggestive of thyroiditis. She was started on
levoT4 (LT4) 0.4 mg/kg per day to reduce goiter volume.
However, after 6 months of treatment (in September
2013), she developed subclinical hyperthyroidism, and
LT4 was slowly weaned off.
In June 2014, 4 months after the LT4 cessation, she
gained weight rapidly (2.5 kg in 2 months), but no other
signs or symptoms of hypothyroidism were reported and
there was no increase in goiter volume. At this time, TSH
was 46 mU/ml, fT4 was 0.5 ng/dl and there was an elevation
in the TRAbs adding to elevated TPO (Table 1). After
3 days, a repeat TSH measurement showed a spontaneous
decrease in TSH to 14.2 mU/ml, without any treatment,
and the scintigraphy showed a homogeneously increased
iodine uptake, suggestive of Graves’ disease. She was again
started on LT4 at 0.73 mg/kg per day. On follow-up after 2
months of LT4 treatment (in August 2014), she was noted
to have a decrease in TSH and an increase in fT4, with no
signs of hyperthyroidism apart from weight loss (Table 1).
She maintained treatment with LT4. Methimazol was
started at a dose of 0.15 mg/kg per day and increased
after 2 months to 0.20 mg/kg per day due to laboratory
evidence of persistent hyperthyroidism. Thyroid function
was controlled with this double therapeutic regimen for a
period of time, but after 6 months she again developed
hyperthyroidism that demanded another adjustment,
with a decrease in LT4 to 0.37 mg/kg and increase in
methimazol to 0.23 mg/kg daily (in July 2015). At this
point, on suspicion of the coexistence of TBAbs and TSAbs
as a cause of these rapid oscillations in thyroid function, a
sample of serum was sent to Hospices Civils de Lyon to
perform a bioassay to measure TSAbs and TBAbs activity
(the method is described in Table 2). The serum level of
TSH was!0.004 mU/ml, fT4 was 3.1 ng/dl and TRAbs were
20 UI/l. A moderate TSAbs activity was detected (203%),
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In this clinical case, there is an alternation between hyper-
and hypothyroidism associated with elevated levels of
antithyroglobulin, antithyroid peroxidase and TRAbs, with
ultrasonographic and scintigraphic findings compatible
both with thyroiditis and Graves’ disease, respectively. A
hyperthyroid state was evident at the early onset in June
2012, with spontaneous remission, and after the beginning
of LT4 therapy in March 2013, to reduce goiter volume.
Effectiveness of LT4 treatment in reducing goiter volume
in euthyroid children and adolescents with autoimmune
thyroid disease is not clear yet, although recent data
supports its use (8, 9). However, due to the possibility of
LT4 overtreatment as a cause of hyperthyroidism noticed
in September 2013, LT4 was slowly weaned off until its
cessation. After a period without treatment, she unexpect-
edly developed hypothyroidism (in June 2014), associated
with elevated levels of TRAbs. Notice also that without any
medication, TSH levels decreased significantly within 3 days
and that at this point scintigraphic findings were compatible
with Graves’ disease. LT4 was restarted and, once again, a
switch to hyperthyroidism was noted right after the
beginning of LT4 that was only reverted with the addition
of methimazol. Further therapeutic adjustments were
needed, due to thyroid function fluctuation over time.
This type of oscillation in thyroid function is
extremely rare, especially in the pediatric age, and is
only described in a few case reports in literature (4, 5).
Takasu & Matsushita (10) admitted that this fluctuation in
thyroid function can be explained by the simultaneous
presence of TSAbs and TBAbs in the sera of the patient. The
balance between both antibodies determines whether a
patient has hypo- or hyperthyroidism (10). McLachlan &
Rapoport (5) advocate that a number of mechanisms may
be behind the pendulum swinging from TBAbs and TSAbs:
i) treatment with LT4; ii) treatment with antithyroid drugs
and iii) inherent properties of TSAbs and TBAbs. In some
patients, LT4 therapy may be associated with an increase in
autoantibody responses due to the effect of LT4 in innate
and adaptive immune responses (5). This may explain the
reason why our patient developed hyperthyroidism in a
short period after she was started on LT4. On the other
hand, treatment with antithyroid drugs, in particular
methimazole, may lead to a decrease in the levels of
thyroid autoantibodies by a direct mechanism of inhi-
bition of its synthesis (5). In this case, no blocking activity
was detected during a hyperthyroid state, 1 year after
double therapy, which may be due to the influence
methimazole in immune responses and antibody3
Table 2 Bioassay descriptions for measurement of TRAbs biological activity (6, 7).
Bioassays location Biology Department of the Hospices Civils de Lyon Sud University Hospital
Procedure The CHO cells (strain JP-26) are transfected with the recombinant human TSH receptor
The CHO JP-26 cells are seeded into 96-well plates (50 000 cells/well), cultured in Ham’s F12 medium,
containing 5% calf serum, and used for TSAb and TBAb bioassays 24 h after seeding
The CHO cells were exposed for 2 h to 4 ml of test serum or control serum in 196 ml with 10 mM
HEPES, 0.25 mmol/l isobutylmethylxanthine, and 0.75% bovine seric albumin, pH 7.4
For the TBAb bioassay, the hypotonic medium was supplemented with bovine TSH (0.1 mIU/ml)
After incubation, cAMP released from the cells was measured with a commercial RIA Kit (RIA cAMP,
IMMUNOTECH, a Beckman Coulter Company, Marseille, France) according to the manufacturer’s
instructions
Pooled TRAb-negative sera (normal sera) were used to measure cAMP basal production, pooled
TSAb-positive sera were used as positive controls in TSAb assay and pooled TBAb-positive sera as
positive controls in TBAb assay
TRAbs biological activity TSAb activity was expressed as a percentage of cAMP basal production
TSAb activities ranging from:
140–200% were considered as weak
200–400% were considered as moderate
R400% were considered as strong
TBAb activity was calculated and expressed as follows: 1 – (a/b)!100, where:
(a) is the cAMP generated in the presence of the patient’s sample and bovine TSH
(b) is the cAMP generated in the presence of normal sera and bovine TSH
TBAb activities ranging from:
10–20% were considered as weak
20–40% were considered as moderate
R40% were considered as strong
The assays were run in triplicate, and results are expressed as the mean of the three data
Variability between assays TSAb activity: 8.6%
TBA activity: 7.1%
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levels. Another important mechanism that might be
involved is the TSAbs’ and TRAbs’ affinities for the TSH
receptor. Clinical status of a patient in a particular point of
time may reflect not only the concentration of both
antibodies, but also their different affinities for the
receptor, and the antibodies with higher concentrations
and affinity will dictate the clinical presentation (5).
The bioassays to determine biological activity of TSAbs
and TBAbs may be very useful to clarify specific situations,
when clinical manifestations suggest the presence of TBAbs.
However, once they are not widely available, and there are
various mechanisms that may influence TBAbs and TSAbs
biologic activity over time, their clinical utility may be
limited in situations of alternating thyroid function. McLa-
chlan & Rapoport (5) emphasize that therapeutic decisions
should be taken according to clinical manifestations and
thyroid function tests, independent of the bioassays results.
The management of this condition is challenging,
and three therapeutic options could be considered: I-131
ablation, thyroidectomy or pharmacological treatment
(single or double therapy). This last option requires
frequent thyroid function monitoring to titrate drugs.
Mathew & Moore (4) reported two similar cases, in a 5- and
an 8-year-old girl in whom an appropriate single drughttp://www.edmcasereports.comregimen failed to control thyroid function. In both cases,
and considering their age, patients underwent a total
thyroidectomy (4). In this case, double therapy briefly
controlled thyroid function, with frequent dose adjust-
ment needed. Definitive treatment with I-131 is being
considered as a suitable option for our patient to avoid the
switches in thyroid function.
Another unexpected fact in this clinical case is the
scintigraphic findings of a homogeneously increased
iodine uptake, suggesting Graves’ disease, during a hypo-
thyroidism state (in June 2014). There are no data in
literature about scintigraphic findings in patients with an
oscillation of thyroid function. One possible explanation is
that the scintigraphywas done in a transitionphase between
hypo- and hyper-thyroidism, once TSH decreased signifi-
cantly within 3 days and TRAbs were elevated. This fact may
lead to an overstimulation of the thyroid that could be
responsible for the homogeneously increased iodine uptake
in scintigraphy. Further studies are needed to confirm this
hypothesis and to better understand this phenomenon.Conclusion
Autoimmune alternating hypo- and hyper-thyroidism is a
highly uncommon challenging condition, particularly in4
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of both TSAbs and TBAbs. The clinical status of the patient
may reflect the balance between these autoantibodies and
can be influenced by their concentration, affinities and
therapeutic interventions (LT4 and antithyroid drugs). The
bioassays that determine biological activity of TSAbs and
TBAbs may be useful; however, their clinical utility is
limited in situations of alternating thyroid function.
Therapeutic decisions should be taken according to clinical
manifestations and thyroid function tests, independent of
the bioassays results. Adding an antithyroid drug to LT4
treatment might be necessary to achieve better thyroid
function control. A definitive treatment should be
considered due to the frequent switches in thyroid
function and the need for close monitoring of pharma-
cological treatment.
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